ArticleKorean journal of family medicine2012
Use of Proton Pump Inhibitor and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies.
Article in Korean journal of family medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Proton pump inhibitors and colorectal cancer: A systematic review.World journal of gastroenterology · 2021Pooled it
- Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies.International journal of colorectal disease · 2020Pooled it
- Knowledge, Attitudes, and Practices of Community Pharmacists Regarding Proton Pump Inhibitor (PPI) Use: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- Article
- Article
- Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study.Scientific reports · 2022Observational
- Association between the chronic use of gastric acid suppressants and high-risk colorectal polyps.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Article
- Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.Journal of gastroenterology · 2020Article
- Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.International journal of molecular sciences · 2019Review
- Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study.PloS one · 2018Article
- Article
- A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival.Current oncology (Toronto, Ont.) · 2016Article
- The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors.International journal of clinical pharmacy · 2015Review
- Comments on statistical issues in november 2012.Korean journal of family medicine · 2012Article
- Prescribing Pattern of Proton Pump Inhibitors in Qatar Rehabilitation Institute: A Retrospective Study.Journal of research in pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious case-control studies have reported inconsistent findings regarding the association between proton pump inhibitor (PPI) use and colorectal cancer (CRC) risk. We investigated these associations using meta-analysis.
methodsWe searched MEDLINE (PubMed), EMBASE, and the Cochrane Library in April 2011. Two evaluators independently reviewed and selected articles, based on pre-determined selection criteria.
resultsOut of 737 articles meeting our initial criteria, 5 case-control studies, which involved 120,091 participants (9,514 cases and 110,577 controls), were included in the final analyses. The overall use of PPI (used vs. never or rarely used) was not significantly associated with the risk of CRC in a fixed-effects model meta-analysis of all 5 case-control studies (odds ratio [OR], 1.08; 95% confidence interval [CI], 0.96 to 1.20; I(2) = 3.5%). Also, in sensitivity meta-analysis by cumulative duration of PPI use, there was no association between PPI use of 1 year or longer and the risk of colorectal cancer in a fixed-effects meta-analysis (OR, 1.09; 95% CI, 0.98 to 1.22; I(2) = 0%).
conclusionAlthough hypergastrinemia could be an important factor in the pathogenesis of some colorectal cancers, our study suggests that this does not lead to significant clinical risk for most PPI users. Further prospective studies or randomized controlled trials related to PPI use and colorectal cancer risk are needed to investigate this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.